CatalystFDA/Bio

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTIN

ENHERTU showed 14.3-month median PFS as first-line therapy in HER2-mutant advanced NSCLC Phase III trial.

What changed

ENHERTU showed 14.3-month median PFS as first-line therapy in HER2-mutant advanced NSCLC Phase III trial.

Why it matters

ENHERTU showed 14.3-month median PFS as first-line therapy in HER2-mutant advanced NSCLC Phase III trial. — impact context not separately stored; see What changed.

Sources

eodhd